Trial · NCT02436668
Adverse events502
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 502
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Anaemia | Blood and lymphatic system disorders | Placebo (Plus Nab-paclitaxel and Gemcitabine) | 95 | 212 | 309 |
| other | Anaemia | Blood and lymphatic system disorders | Ibrutinib (Plus Nab-paclitaxel and Gemcitabine) | 90 | 208 | 289 |
| other | Thrombocytopenia | Blood and lymphatic system disorders | Placebo (Plus Nab-paclitaxel and Gemcitabine) | 55 | 212 | 208 |
| other | Thrombocytopenia | Blood and lymphatic system disorders | Ibrutinib (Plus Nab-paclitaxel and Gemcitabine) | 75 | 208 | 221 |
| other | Neutropenia | Blood and lymphatic system disorders | Placebo (Plus Nab-paclitaxel and Gemcitabine) | 84 | 212 | 328 |
| other | Neutropenia | Blood and lymphatic system disorders | Ibrutinib (Plus Nab-paclitaxel and Gemcitabine) | 68 | 208 | 139 |
| other | Leukopenia | Blood and lymphatic system disorders | Placebo (Plus Nab-paclitaxel and Gemcitabine) | 18 | 212 | 61 |
| other | Leukopenia | Blood and lymphatic system disorders | Ibrutinib (Plus Nab-paclitaxel and Gemcitabine) | 15 | 208 | 19 |
| other | Vision blurred | Eye disorders | Placebo (Plus Nab-paclitaxel and Gemcitabine) | 15 | 212 | 18 |
| other | Vision blurred | Eye disorders | Ibrutinib (Plus Nab-paclitaxel and Gemcitabine) | 17 | 208 | 20 |
| other | Diarrhoea | Gastrointestinal disorders | Placebo (Plus Nab-paclitaxel and Gemcitabine) | 109 | 212 | 240 |
| other | Diarrhoea | Gastrointestinal disorders | Ibrutinib (Plus Nab-paclitaxel and Gemcitabine) | 147 | 208 | 357 |
| other | Nausea | Gastrointestinal disorders | Placebo (Plus Nab-paclitaxel and Gemcitabine) | 107 | 212 | 242 |
| other | Nausea | Gastrointestinal disorders | Ibrutinib (Plus Nab-paclitaxel and Gemcitabine) | 116 | 208 | 228 |
| other | Vomiting | Gastrointestinal disorders | Placebo (Plus Nab-paclitaxel and Gemcitabine) | 86 | 212 | 184 |
| other | Vomiting | Gastrointestinal disorders | Ibrutinib (Plus Nab-paclitaxel and Gemcitabine) | 85 | 208 | 169 |
| other | Constipation | Gastrointestinal disorders | Placebo (Plus Nab-paclitaxel and Gemcitabine) | 78 | 212 | 96 |
| other | Constipation | Gastrointestinal disorders | Ibrutinib (Plus Nab-paclitaxel and Gemcitabine) | 68 | 208 | 91 |
| other | Abdominal pain | Gastrointestinal disorders | Placebo (Plus Nab-paclitaxel and Gemcitabine) | 67 | 212 | 99 |
| other | Abdominal pain | Gastrointestinal disorders | Ibrutinib (Plus Nab-paclitaxel and Gemcitabine) | 63 | 208 | 94 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02436668/events